Author Archives
-
Workshop 21 April 2022 Sex differences in AF
After two years of digital meetings it was a true pleasure to meet so many of you at Felix conference center in Oslo for the annual afib.no workshop! We enjoyed two outstanding keynote lectures from dr. Vera Regitz-Zagrosek, Berlin, Germany… Read More ›
-
NEXAF workshop 20.04.2022
With support from afib.no, the researchers in The Norwegian Exercise and Atrial Fibrillation Initiative NEXAF, met for the first NEXAF workshop in Oslo earlier this month. Researchers from all the three NEXAF-studies, and from the research institutions The Arctic University… Read More ›
-
Two network members have defended their thesis – Congratulations!
Are Annesønn Kalstad at Institute of Clinical Medicine defended his thesis “The role of n-3 fatty acids in cardiovascular diseases of ageing” for the degree of PhD (Philosophiae Doctor). Jan. 28, 2022Read more here. MD Ole-Christian Walter Rutherford at Institute… Read More ›
-
Congratulation to Laura K. Andreasen
MD Laura K. Andreasen defended her PhD entitled “Genome-wide association studies of the left atrium and supraventricular tachycardias” the 18th of February 2022. The thesis includes three genome-wide association studies on 1) the left atrium assessed with cardiac magnetic resonance… Read More ›
-
Increasing n-3 PUFA levels linked to risk of atrial fibrillation in the OMEMI trial
The OMEMI (Omega-3 Fatty acids in Elderly with Myocardial Infarction) trial was performed by several members of the afib.no network. In the trial, elderly patients with a recent myocardial infarction were randomized to 1.8 g/day of n-3 polyunsaturated fatty acids… Read More ›
-
Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology
Edvard Liljedahl Sandberg: The primary aim of this study was to evaluate the diagnostic accuracy and usability of ECG247 Smart Heart Sensor compared to conventional Holter monitoring. Patients > 18 years of age referred for out-of-hospital long-term ECG recording regardless of… Read More ›
-
Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data
In this study we looked at clinical outcomes of patients who underwent cardioversion in the non-interventional Global Anticoagulant Registry in the FIELD-AF (GARFIELD-AF). 44 201 patients were included in an analysis comparing patients who received a baseline cardioversion with those… Read More ›
-
afib.no annual meeting 2021
Thank you all for tuning in to this year’s afib.no meeting! We were thrilled to see so many of you there and impressed by the quality of the presentations. Day 1 started with the team behind the NEXAF study, who… Read More ›
-
Pro@Heart Symposium in Leuven, Belgium
Network members Eivind Sørensen (The Birkebeiner II Study), Turid Apelland, André La Gerche and Marius Myrstad (The NEXAF Detraining Study) attended the Pro@Heart Symposium in Leuven, Belgium September 24-26 2021. “Protecting the athlete by improving our understanding of athlete’s physiology”… Read More ›
-
High persistence and adherence among NOAC users
High persistence and adherence among NOAC users Adequate persistence and adherence with non-vitamin K antagonists (NOACs) is essential for optimal stroke prevention in atrial fibrillation (AF), but large-scale studies comparing the different NOACs has been lacking. In a study recently… Read More ›
afib.no 